Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigen
US5078998A · kind A · utility
34Cited by
0References
13Claims
0Family size
Inventors
Key dates
| Filing date | Aug 2, 1985 |
| Grant date | Jan 7, 1992 |
| Priority date | — |
| Expiry date | Aug 2, 2005 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A hybrid ligand molecular composed of an antibody combining site that binds to a T cell receptor complex structure and is capable of activating cytotoxic T lymphocytes linked to a target cell-specific antibody is disclosed. This ligand molecule can bind to an antigen on the surface of a target cell and to cytotoxic effector T lymphocyte cell receptor complex structures. A composition and a method for killing tumor cells with the hybrid ligand molecule of this invention are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.